Drug firm Lupin has launched its Metformin HCl tablets, a diabetes drug, in the US market and is eligible for 180 days exclusivity for the product.
"The company's US subsidiary Lupin Pharmaceuticals Inc has launched its Metformin HCl extended release tablets in the strengths of 500 mg and 1,000 mg," Lupin said in a BSE filing.
The company's products are generic equivalent to Santarus Inc's Glumetza HCl ER tablets in the same strengths, it added.
"Glumetza HCl ER tablets had US sales of USD 450.4 million (as per IMS MAT September 2015)," Lupin said.
The product is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type II diabetes mellitus, it added.
Shares of Lupin Ltd today closed at Rs 1,706.15 apiece on BSE, up 0.28 per cent from its previous close.
